CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer
CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer is a paper indexed in PICO Portal from OpenAlex.
How many citations does CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer have?
CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer has 56 citations in the OpenAlex counts PICO Portal stores.
When was CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer published?
CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer has 2015 year in the PICO Portal index.
What is the open-access status of CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer?
CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer has closed oa status in the PICO Portal index.
What is the DOI of CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer?
The DOI for CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer is on the source record.
What is the PMID of CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer?
The PMID for CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer is on the source record.
What is the OpenAlex record for CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer?
The OpenAlex for CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer is on the source record.